04.11.2009
Evolva closed its Series B financing round
Evolva SA, a biotech company with headquarters near Basel / Switzerland announced a CHF 28 million first closing of its Series B financing round.
Evolva SA uses its genetic chemistry platform to replicate, on an industrial basis, the ability of nature to create small molecules with exquisite “design”.
The company received the CTI Start-up Label in November 2006.
The Series B financing is led by current investor Aravis and new investors Auriga Partners, Vinci Capital - Renaissance PME and Wellington Partners. BioMedInvest and an undisclosed private investor participated as co-investors in the first closing, as well as Evolva's existing investors Astellas Venture, Dansk Innovation, Novartis Bioventures and Sunstone Capital.
"We are impressed by Evolva's innovative technology, the interesting compounds pipeline and its international business model," commented Patrick Scherrer representing Vinci Capital - Renaissance PME. "We have confidence in the great potential of Evolva's approach and consequently have decided to engage with the company."
Evolva SA counts 12 employees and has signed in September 2009 an agreement with Arpida Ltd. (SIX: ARPN) in Reinach near Basel to merge.
More information about Evolva on http://www.evolva.com/